4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Peanut Allergy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 82 ongoing clinical trials involving Peanut Allergy
Of the 82 trials,44 trials are in Phase III
Furthermore, 19 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Peanut Allergy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Peanut Allergy, an Immunology condition. The largest number of ongoing clinical trials for Peanut Allergy are conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Peanut Allergy-related drug trials.

DBV Technologies SA and Aimmune Therapeutics Inc: The leading ongoing Peanut Allergy related clinical trial sponsors

DBV Technologies SA and Aimmune Therapeutics Inc are the top sponsors for Peanut Allergy-related ongoing clinical trials.

University of Chicago, Helsinki University Central Hospital, The National Institute of Allergy and Infectious Diseases and Icahn School of Medicine at Mount Sinai are among other notable clinical trial sponsors involved in Peanut Allergy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Peanut Allergy

Peanut (Arachis hypogaea) (Palforzia) is the key marketed drug involving Peanut Allergy.

Peanut (Arachis hypogaea) (Palforzia) Allergen is an immunotherapy agent. Peanut is formulated as powder in capsules for oral route of administration. Palforzia is indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 years and over. Peanut was first approved in 2020 and is marketed globally in the US, UK, Belgium, Italy, Germany, and France by Aimmune Therapeutics Inc.